Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Core Scientific (CORZ) over the last 5 years, with Q3 2025 value amounting to $244.5 million.

  • Core Scientific's Capital Expenditures rose 68428.5% to $244.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $483.0 million, marking a year-over-year increase of 52037.82%. This contributed to the annual value of $95.0 million for FY2024, which is 48759.36% up from last year.
  • Latest data reveals that Core Scientific reported Capital Expenditures of $244.5 million as of Q3 2025, which was up 68428.5% from $121.3 million recorded in Q2 2025.
  • Core Scientific's 5-year Capital Expenditures high stood at $244.5 million for Q3 2025, and its period low was -$116.1 million during Q4 2021.
  • Moreover, its 5-year median value for Capital Expenditures was $28.8 million (2024), whereas its average is $50.0 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 9977.69% in 2023, then soared by 376854.86% in 2025.
  • Quarter analysis of 5 years shows Core Scientific's Capital Expenditures stood at -$116.1 million in 2021, then skyrocketed by 220.81% to $140.2 million in 2022, then tumbled by 91.7% to $11.6 million in 2023, then surged by 146.96% to $28.8 million in 2024, then soared by 750.17% to $244.5 million in 2025.
  • Its Capital Expenditures was $244.5 million in Q3 2025, compared to $121.3 million in Q2 2025 and $88.4 million in Q1 2025.